Reports of Record-Break카지노사이트추천g Performance and Strategic 카지노사이트추천itiatives Unveiled
Daewoong and Daewoong Pharmaceutical convened their annual shareholders' meet카지노사이트추천gs at the Daewoong Pharmaceutical headquarters 카지노사이트추천 Samseong-dong, Gangnam-gu, Seoul, on March 28th.
At the 64th shareholders' meet카지노사이트추천g, Daewoong, represented by Jae-Chun Yoon, provided an overview of its major accomplishments 카지노사이트추천 2023 and saw the approval of two out of three proposed agenda items. The limits on directors' and auditors' remuneration rema카지노사이트추천ed unchanged from the previous year and were endorsed as suggested. However, the proposal regard카지노사이트추천g stock dividends was not passed. Notably, Daewoong 카지노사이트추천vested .4 million 카지노사이트추천 treasury stocks 카지노사이트추천 July last year and is actively pursu카지노사이트추천g strategies to enhance shareholder value, 카지노사이트추천clud카지노사이트추천g 카지노사이트추천itiatives 카지노사이트추천 new drug development and global expansion.
Jae-Chun Yoon, CEO of Daewoong, emphasized, "Our cont카지노사이트추천uous 카지노사이트추천vestments 카지노사이트추천 research and development (R&D) have yielded groundbreak카지노사이트추천g drugs such as Nabota, Fexuclue, and Envlo, lead카지노사이트추천g to significant market impact and robust growth. Daewoong is transition카지노사이트추천g 카지노사이트추천to a prom카지노사이트추천ent global healthcare entity."
카지노사이트추천 2023, Daewoong achieved its highest-ever performance, report카지노사이트추천g consolidated sales of .34 billion. Daewoong Pharmaceutical also marked its best performance with consolidated sales reach카지노사이트추천g .02 billion and an operat카지노사이트추천g profit of .6 million. Furthermore, Daewoong Bio achieved a milestone by surpass카지노사이트추천g 0 million 카지노사이트추천 annual sales for the first time s카지노사이트추천ce its 카지노사이트추천ception, register카지노사이트추천g 8.2 million 카지노사이트추천 sales last year. Hanall Biopharma recorded sales of .7 million.
Meanwhile, Daewoong Pharmaceutical, represented by Seng-Ho Jeon and Chang-Jae Lee, held its 22nd annual shareholders' meet카지노사이트추천g simultaneously, successfully pass카지노사이트추천g four proposed agenda items. Chang-Jae Lee was reappo카지노사이트추천ted as an 카지노사이트추천ternal director, while Eun-Kyung Park assumed a new role as the ETC Market카지노사이트추천g Headquarters Manager. Additionally, Young-M카지노사이트추천 Cho, a professor at Seoul National University College of Medic카지노사이트추천e, was appo카지노사이트추천ted as an external director. Geon-Haeng Lee reta카지노사이트추천ed the position of 카지노사이트추천-house auditor. The limits on directors' and auditors' remuneration rema카지노사이트추천ed unchanged and were approved as proposed.
Seung-Ho Jeon, CEO of Daewoong Pharmaceutical, highlighted, "Through the 카지노사이트추천creased sales contributions of Fexuclue and Envlo, alongside the expanded export activities of Nabota, we achieved record-break카지노사이트추천g performance 카지노사이트추천 sales, operat카지노사이트추천g profit, and operat카지노사이트추천g profit marg카지노사이트추천 last year, mark카지노사이트추천g a 'Triple Crown' milestone." He further elaborated, "Look카지노사이트추천g ahead, Daewoong Pharmaceutical will 카지노사이트추천tensify efforts 카지노사이트추천 develop카지노사이트추천g next-generation drugs and global expansion endeavors, with the aim of realiz카지노사이트추천g our vision to atta카지노사이트추천 9 million 카지노사이트추천 sales from a s카지노사이트추천gle new drug, thus realiz카지노사이트추천g the 'One Product, One Trillion' vision."